Top News
-
November 18, 2022Elpiscience Announces Studies Presented at SITC 2022 Annual MeetingLearn More -
October 26, 2022Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual MeetingLearn More -
May 09, 2022Elpiscience Announces FDA IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid TumorsLearn More
Our Pipeline
Elpiscience has a robust pipeline of globally innovative cancer immunotherapies, covering a wide range of oncology targets. Through internal R&D expertise and partnerships with global biopharmaceutical companies, Elpiscience endeavors to advance at least one innovative program into the clinic each year.
Learn More
Our Science
Elpiscience has established comprehensive R&D capabilities including proprietary monoclonal and bispecific antibody discovery, translational research, clinical development. Our integrated R&D engine enables us to advance our innovative programs rapidly and cost-effectively.
Learn More
Partnering
Elpiscience collaborates with global biopharmaceutical and biotechnology companies, academic institutions, and clinicians to accelerate the development of innovative cancer immunotherapies.
Careers
Elpiscience fosters an inclusive work environment comprised of diverse, committed, and highly accomplished professionals. Together, we live Elpiscience’s values as we advance scientific innovation and develop transformative medicines that improve cancer patients’ lives.
Learn More
